SOD1 and Alzheimer disease: TZDs pioglitazone and rosiglitazone reduce oxidative markers (MDA, lipid peroxidation and nitrite), restore glutathione levels and promote SOD activity in STZ- and scopolamine-induced AD models [125, 126, 129, 130, 291, 292].